Valentina Boscaro
Researcher
- Department of Drug Science and Technology
- SSD: BIO/14 - pharmacology
- ORCID: orcid.org/0000-0002-3344-8624
Contacts
- 011-6706865 / 7182
- 011-6707153
- valentina.boscaro@unito.it
- corso Raffaello, 33 - 3^ piano
- https://www.dstfen.unito.it/persone/valentina.boscaro
- Contacts VCard
At
- Department of Drug Science and Technology
- Dipartimento di Scienza e Tecnologia del Farmaco
- Corsi di studio in
Farmacia - Chimica e tecnologia farmaceutiche
Curriculum vitae
Selected research products
Gastaldi S, Rocca C, Gianquinto E, Granieri MC, Boscaro V, Blua F, Rolando B, Marini E, Gallicchio M, De Bartolo A, Romeo N, Mazza R, Fedele F, Pagliaro P, Penna C, Spyrakis F, Bertinaria M, Angelone T. (2023) Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation. European journal of medicinal chemistry 257 115542 [DOI PMID]
Boscaro V, Rivoira M, Sgorbini B, Bordano V, Dadone F, Gallicchio M, Pons A, Benetti E, Rosa AC. (2022) Evidence-Based Anti-Diabetic Properties of Plant from the Occitan Valleys of the Piedmont Alps. Pharmaceutics 14(11) [DOI PMID]
Boscaro V, Barge A, Deagostino A, Ghibaudi E, Laurenti E, Marabello D, Diana E, Gallicchio M. (2021) Effects of Vanadyl Complexes with Acetylacetonate Derivatives on Non-Tumor and Tumor Cell Lines. Molecules (Basel, Switzerland) 26(18) [DOI PMID]
Gastaldi S, Boscaro V, Gianquinto E, Sandall CF, Giorgis M, Marini E, Blua F, Gallicchio M, Spyrakis F, MacDonald JA, Bertinaria M. (2021) Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor. Molecules (Basel, Switzerland) 26(13) [DOI PMID]
Lolli ML, Carnovale IM, Pippione AC, Wahlgren WY, Bonanni D, Marini E, Zonari D, Gallicchio M, Boscaro V, Goyal P, Friemann R, Rolando B, Bagnati R, Adinolfi S, Oliaro-Bosso S, Boschi D. (2019) Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3. ACS medicinal chemistry letters 10(4) 437-443 [DOI PMID]
Rosa AC, Benetti E, Gallicchio M, Boscaro V, Cangemi L, Dianzani C, Miglio G. (2019) Analyzing Cysteine Site Neighbors in Proteins to Reveal Dimethyl Fumarate Targets. Proteomics 19(4) e1800301 [DOI PMID]
Boscaro V, Boffa L, Binello A, Amisano G, Fornasero S, Cravotto G, Gallicchio M. (2018) Antiproliferative, Proapoptotic, Antioxidant and Antimicrobial Effects of Sinapis nigra L. and Sinapis alba L. Extracts. Molecules (Basel, Switzerland) 23(11) [DOI PMID]
Lovisari M, Volpi G, Marabello D, Cadamuro S, Deagostino A, Diana E, Barge A, Gallicchio M, Boscaro V, Ghibaudi E. (2017) EPR and photophysical characterization of six bioactive oxidovanadium(IV) complexes in the conditions of in vitro cell tests. Journal of inorganic biochemistry 170 55-62 [DOI PMID]
Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. (2016) Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer research 76(15) 4504-15 [DOI PMID]
Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F. (2013) BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Molecular cancer therapeutics 12(12) 2950-61 [DOI PMID]
Sgarbossa S, Diana E, Marabello D, Deagostino A, Cadamuro S, Barge A, Laurenti E, Gallicchio M, Boscaro V, Ghibaudi E. (2013) Synthesis, characterization and cell viability test of six vanadyl complexes with acetylacetonate derivatives. Journal of inorganic biochemistry 128 26-37 [DOI PMID]
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404) 532-6 [DOI PMID]
Courses
- FARMACOLOGIA SPERIMENTALE (STF0253)
Corsi di studio in
Farmacia - Chimica e tecnologia farmaceutiche - Farmacognosia con elementi di Farmacologia generale (Farmacia) (STF0049)
Corsi di studio in
Farmacia - Chimica e tecnologia farmaceutiche
Research topics
- Pharmacological characterization of cannabinoids and cannabidiol-derived compounds in human cell lines
- Pharmacological characterization of new inhibitors of NLRP3 activation in differentiated THP-1
- Characterization of dual compounds with inhibitory activity on EGFR on coloncancer cell lines harboring different mutations on EGFR signaling pathway
- Evaluation of toxic effects of drug contaminants present in Antarctic-seawater on different type of cell lines
- Ecotoxicological evaluationof effects of Organic UV filters on different type of cell lines
- Evaluation of pharmacological activity of AKR1C inhibitors on colon cancer tumor cell lines, alone or in association with anticancer drugs used in the treatment of colorectal cancer
Research groups
Research projects
- Characterization, mechanism of action and structure-property relationship studies of new V(IV)complexes as potential anticancer agents. [VIVA]
- Understanding the molecular bases of secondary resistance to EGFR targeted therapies in colorectal cancer
- Contaminanti emergenti nel Mare di Ross: distribuzione, sorgenti e rischi ecorossicologici
Activities in agenda
Academic bodies
Office hours
Previo appuntamento, concordato telefonicamente o via e-mail